United States· US:72579-121_d46bfb2e-44c4-4a86-8a8f-b38fb01ac4b6
TEVIMBRA
A tislelizumab product containing tislelizumab, registered in United States by BeOne Medicines USA, Inc.. The same ATC class is registered in 12 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Tislelizumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF09 (tislelizumab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Tislelizumab · ATC L01FF09
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of tislelizumab costs, country by country.
Normalised to the WHO defined daily dose (9.5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tislelizumab · price per daily dose (9.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$204.40
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- TISLELIZUMAB
- Manufacturer
- BeOne Medicines USA, Inc.
- Country
- United States (US)
- ATC code
- L01FF09
- ATC class
- Tislelizumab
- Defined daily dose
- 9.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc1172579-121-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tislelizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandTevimbraBeiGene Ireland Ltd.
- CzechiaTEVIMBRABeOne Medicines Ireland Limited, Dublin
- BelgiumTevimbra 100 mgBeOne Medicines Ireland
- FinlandTevimbraBeOne Medicines Ireland Limited
- FranceTEVIMBRA 100 mg, solution à diluer pour perfusionBEONE MEDICINES IRELAND (IRLANDE)
- IrelandTevimbra 100 mg concentrate for solution for infusionBeiGene Ireland Limited
- IcelandTevimbraBeigene Ireland Limited
- Japanチスレリズマブ（遺伝子組換え）ビーワン・メディシンズ
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Tevimbra
- Norway · Tevimbra
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e1f93e60-99e2-42f9-8ce3-560310a628fe GET /v1/drugs/e1f93e60-99e2-42f9-8ce3-560310a628fe?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "10",
"substance": "TISLELIZUMAB",
"productndc": "72579-121",
"dosage_form": "INJECTION, SOLUTION, CONCENTRATE",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA761232",
"marketing_category": "BLA"
}See everything about tislelizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.